Big pharma

An antiviral targeting the dengue virus was quietly abandoned by industry, but it's now suddenly back in the spotlight. A new study suggests it didn’t just slow the dengue virus, it blocked viral replication and reduced infection rates at high doses.

After the FDA proposed pulling some cold and flu medications from shelves in the US, an Australian law firm has launched a class action against Johnson & Johnson, claiming that it has knowingly marketed and sold ineffective decongestants for years.